A series of seventeen novel hydroxamic acids incorporating 1-((1H -1,2,3-triazol-4-yl)methyl)-3-hydroxyimino-indolin-2-ones was designed and synthesized. Biological evaluation showed that these hydroxamic acids potently inhibited a class-I isoform of HDACs (HDAC2) with IC 50 values in low micromolar range. Several compounds also exhibited good cytotoxicity. Two compounds, 5e and 5f, emerged as the most potent HDAC2 inhibitors with cytotoxicity up to 8-fold more potent than SAHA in three human cancer cell lines, including SW620 (colon cancer), PC3 (prostate cancer) and AsPC-1 (pancreatic cancer). A molecular modeling approach has been carried out which revealed some structure-activity relationships. Further investigation on absorption, distribution, metabolism, excretion and toxicity (ADMET) suggested that compounds 5e and 5f, while showing potent HDAC2 inhibitory bioactivity, hold desirable characteristics for anticancer compounds.
Introduction
Target-based drug design and discovery has become a main stream in today's new drug discovery and development. In the field of cancer research, thanks to the recent advances in molecular pathology, hundreds of proteins have been validated as potential molecular targets for anticancer drug design. These include protein kinases, farnesyltransferases, telomerases, and histone deacetylases, among many others. 1 Histone deacetylases (HDAC) are a group of enzymes catalyzing removal of the acetyl groups from lysine residues in the tails of histone proteins. 2, 3 Hitherto, 18 different isoforms of HDACs have been identified in eukaryotes and these isoforms are categorized * 
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into four classes based on the relative sequence similarity. [2] [3] [4] Among these four classes, class I of HDACs, which has four members (HDAC1, 2, 3 and HDAC8) and class II, which has six members (HDAC4, 5, 6, 7, 9 and HDAC10) have been comprehensively investigated and demonstrated to be deeply involved in a number of cell-related processes. [3] [4] [5] Specifically, HDAC 1, 2, 3 and 8 have been shown to promote cellular proliferation, meanwhile HDAC 1-4, 5 and 8 prevent cellular apoptosis and differentiation. Other HDAC isoforms, for example, HDAC 4, 6, 7 and 10, have been demonstrated to promote angiogenesis and cell migration, two processes very important for cancer cell metastasis. 4, 5 Down-regulation of these HDAC isoforms has been shown to result in a number of events related to differentiation, apoptosis and cell cycle arrest in different types of tumor cells. 6 Moreover, selective suppression of the growth of tumor cells caused by HDAC inhibition has been clearly demonstrated not only in vitro but also in a number of in vivo preclinical models and clinical settings. 6 Design of compounds to inhibit appropriate HDACs has, therefore, become a very interesting approach in cancer drug design and development nowadays. 7 As a result, a number of HDAC inhibitors have been reported in the past decades. These inhibitors are diverse, from short-chain fatty acids (like butyrate, phenylbutyrate or valproic acid) to hydroxamic acids, or benzamides. [8] [9] [10] [11] [12] [13] [14] To date, at least 4 HDAC inhibitors have been approved for use in clinical settings. The first HDAC inhibitor approved by the U.S. FDA in October 2006 for the treatment of cutaneous T cell lymphoma (CTCL) was vorinostat (trade name, Zolinza®) (also known as SAHA or suberoylanilidehydroxamic acid) ( Figure 1 ). In 2009, the second HDAC inhibitor, romidepsin (trade name, Istodax®) was also approved by the U.S. FDA for the same indication. In Feb 2015, panobinostat (LBH-589, trade name Farydak®) was licensed by the US FDA for the treatment of multiple myeloma. 15 Also in 2015 chidamide (Epidaza®) was approved by the Chinese FDA for relapsed or refractory peripheral T cell lymphoma. 16 In addition, a number of other HDAC inhibitors such as PXD-01 (belinostat), MS-27-527 (entinostat) (Figure 1 ) are currently under different phases of clinical trials for several types of cancer ( Figure 1 ).
In continuation of our research program to develop novel hydroxamic acids as potential inhibitors of HDACs and anticancer agents, we have designed, synthesized and evaluated several series of heterocyclic analogues of SAHA, which incorporated benzothiazole or 5-aryl-1,3,4-thiadiazole systems ( Figure 2 ). These compounds exhibited very potent HDAC inhibitory activity as well as cytotoxicity. [17] [18] [19] [20] Several representative compounds from these series also demonstrated very potent antitumor activity in PC-3 prostate cancer cells xenografted mice model. 18 Encouraged by these results, we expanded our design to the new series of 17 hydroxamic acids. In these hydroxamic acids the 2-oxoindoline system is employed as a cap group and linkers of different lengths incorporating a triazole moiety are probed. The current paper reports the results we obtained from the synthesis, biological evaluation and computational study on these novel hydroxamic acids.
Experimental
Chemistry
2.1a Chemicals and instruments:
Thin layer chromatography (TLC) was performed using Whatman ® 250 µm Silica Gel GF Uniplates and visualized under UV light at 254 and 365 nm. TLC was used to check the progress of reactions and preliminary evaluation of compounds' homogeneity. Melting points were measured using a Gallenkamp Melting Point Apparatus (LabMerchant, London, United Kingdom) and are uncorrected. Purification of compounds was carried out using crystallization methods and/or open silica gel column flash chromatography employing Merck silica gel 60 (240 to 400 mesh) as stationary phase. Nuclear magnetic resonance spectra ( 1 H NMR) were recorded on a Bruker 500 MHz spectrometer with DMSO-d 6 as solvent unless otherwise indicated. Tetramethylsilane was used as an internal standard. Chemical shifts are reported in parts per million (ppm), downfield from tetramethylsilane. The elemental (C, H, N) analyses were performed on a Perkin Elmer model 2400 elemental analyzer. IR spectra were recorded on a Perkin Elmer FTIR model RX1 spectrometer (KBr disc, 4000−400 cm −1 ). Mass spectra with different ionization modes including electron ionization (EI), Electrospray ionization (ESI), were recorded using PE Biosystems API2000 (Perkin Elmer, Palo Alto, CA, USA) and Mariner® (Azco Biotech, Inc.Oceanside, CA, USA) mass spectrometers, respectively. All the reagents (of synthetic grade with purity of 97% minimum) and solvents (of technical grade) were purchased from Aldrich, Fluka Chemical Corp. (Milwaukee, WI, USA) or Merck unless noted otherwise. Solvents were used directly as purchased unless otherwise indicated.
2.1b General procedures for the synthesis of compounds 4-6:
The synthesis of the series of 17 Nhydroxyalkanamides incorporating 1-((1H -1,2,3-triazol-4-yl)methyl)-3-hydroxyiminoindolin-2-one moities (4-6) was carried out as illustrated in Scheme 1. Details are as follows:
To the respective solution of isatins 1a-g (1 mmol) in DMF (3 mL) were added K 2 CO 3 (165.5 mg, 1.2 mmol). The resulting mixtures were stirred at 80 • C for 1 h, then KI (8.3 mg, 0.05 mmol) was added. After stirring for further 15 min, 0.15 mL of a solution of propargyl bromide 80% in toluene was added dropwise slowly into the mixtures. The reaction mixtures were again stirred at 60 • C for 3 h. Upon completion of the reaction, the resulting mixtures were cooled, poured into ice-cold water and acidified to pH∼4. The orange solids formed were filtered and dried to give the propargylatedisatins 2, which were used for the next step without further purification.
A respective solution of compounds 2 and methyl azidoesters (1 mmol) in acetonitrile (2 mL) was stirred at room temperature for 10 min, then CuI (19.1 mg, 0.1 mmol) was added. The mixture was stirred at 50 • C until the reaction completed (12-24 h). The corresponding resulting mixtures were evaporated under reduced pressure to give the residues, which were re-dissolved in 50 mL of DCM. The mixtures were filtered and the DCM layers were evaporated under reduced pressure to give the intermediate esters 3, which were dissolved in a mixture of methanol and tetrahydrofuran (2/1, 5 mL). Then, hydroxylamine.HCl (685 mg, 10 mmol) was added, followed by dropwise addition of a solution of NaOH (400 mg in 1 mL of water). The mixtures were stirred at room temperature until the reaction completed. The resulting reaction mixtures were poured into ice-cold water, neutralised to pH ∼ 7 and acidified by dropwise addition of a solution of HCl 5% to induce precipitation. The precipitates were filtered, dried and re-crystallized in methanol to give the target compounds 4-6. (3-(hydroxyimino)-5-methyl-2-oxoindolin-1-yl)methyl)-1H-1,2,3-triazol-1-yl) 
2.1.2a N-Hydroxy
-3-(4-((3-(hydroxyimino)-2-oxoindo- lin-1-yl)methyl)-1H-1,2,3-triazol-1-yl)propanamide (4a):
2.1.2b 3-(4-((
5-Fluoro-3-(hydroxyimino)-2-oxoindolin- 1-yl)methyl)-1H-1,2,3-triazol-1-yl)-N-hydroxypropan- amide (4b):
2.1.2c 3-(4-((
5-Chloro-3-(hydroxyimino)-2-oxoindolin- 1-yl)methyl)-1H-1,2,3-triazol-1-yl)-N-hydroxypropan- amide
2.1.2e 4-(4-((5-Fluoro-3-(hydroxyimino)-2-oxoindolin-1-yl)methyl)-1H-1,2,3-triazol-1-yl)-N-hydroxybutanamide
2.1.2f 4-(4-((5-Chloro-3-(hydroxyimino)-2-oxoindolin-1-yl)methyl)-1H-1,2,3-triazol-1-yl)-N-hydroxybutanamide
2.1.2g 4-(4-((5-Bromo-3-(hydroxyimino)-2-oxoindolin-
1-yl)methyl)-1H-1,2,3-triazol-1-yl)-N-hydroxybutan- amide (5d):
2.1.2h N-Hydroxy-4-(4-((3-(hydroxyimino)-5-methyl-2-oxoindolin-1-yl)methyl)-1H-1,2,3-triazol-1-yl)butanamide
2.1.2i N-Hydroxy-4-(4-((3-(hydroxyimino)-5-methoxy-
2-oxoindolin-1-yl)methyl)-1H-1,2,3-triazol-1-yl)butan- amide (5f ):
2.1.2j 4-(4-((7-Chloro-3-(hydroxyimino)-2-oxoindolin-
1-yl)methyl)-1H-1,2,3-triazol-1-yl)-N-hydroxybutan- amide (5g):
2.1.2k N-Hydroxy-5-(4-((3-(hydroxyimino)-2-oxoindolin-1-yl)methyl)-1H-1,2,3-triazol-1-yl)pentanamide
2.1.2l 5-(4-((5-Fluoro
-3-(hydroxyimino)-2-oxoindolin- 1-yl)methyl)-1H-1,2,3-triazol-1-yl)-N-hydroxypentan- amide (6b):
2.1.2m 5-(4-((5-
Chloro
2.1.2n 5-(4-((5-
Bromo6"); 7.09 (1H, d, J = 7.75 Hz, H-7"); 4.98 (2H, s, H-6'a,
2.1.2o N-Hydroxy-5-(4-(
2.1.2p N-Hydroxy-5-(4-((3-(hydroxyimino)-5-methoxy-2-oxoindolin-1-yl)methyl)-1H-1,2,3-triazol-1-yl)pentanamide
2.1.2q 5-(4-((7-Chloro-3-(hydroxyimino)-2-oxoindolin-1-yl)methyl)-1H-1,2,3-triazol-1-yl)-N-hydroxypentanamide
Biological evaluation
2.2a Cytotoxicity assay:
The cytotoxicity of the synthesized compounds was evaluated against three human cancer cell lines, including SW620 (colon cancer), PC3 (prostate cancer), and AsPC-1 (pancreatic cancer). The cell lines were purchased from a Cancer Cell Bank at the Korea Research Institute of Bioscience and Biotechnology (KRIBB). The media, sera and other reagents that were used for cell culture in this assay were obtained from GIBCO Co. Ltd. (Grand Island, New York, USA).The cells were culture in DMEM (Dulbecco's Modified Eagle Medium) until confluence. The cells were then trypsinized and suspended at 3 × 10 4 cells/mL of cell culture medium. On day 0, each well of the 96-well plates was seeded with 180 µL of cell suspension. The plates were then incubated in a 5% CO 2 incubator at 37 • C for 24 h. Compounds were initially dissolved in dimethyl sulfoxide (DMSO) and diluted to appropriate concentrations by culture medium. Then 20 µL of each sample of compounds, which were prepared as described above, were added to each well of the 96-well plates, which had been seeded with cell suspension and incubated for 24 h, at various concentrations. The plates were further incubated for 48 h. Cytotoxicity of the compounds was measured by the colorimetric method, as described previously. 21 with slight modifications. [22] [23] [24] The IC 50 values were calculated using a Probits method, 25 taking average values from three independent determinations (SD ≤ 10%).
2.2b HDAC2 enzyme assay:
The HDAC2 enzyme was purchased from BPS Bioscience (San Diego, CA, USA). The HDAC enzymatic assay was performed using a Fluorogenic HDAC Assay Kit (BPS Bioscience) according to the manufacturer's instructions. Briefly, HDAC2 enzymes were incubated with vehicle or various concentrations of the assayed samples or SAHA for 30 min at 37 • C in the presence of an HDAC fluorimetric substrate. The HDAC assay developer (which produces a fluorophore in reaction mixture) was added, and the fluorescence was measured using VICTOR 3 (PerkinElmer, Waltham, MA, USA) with excitation at 360 nm and emission at 460 nm. The measured activities were subtracted by the vehicle-treated control enzyme activities and IC 50 values were calculated using GraphPad Prism (GraphPad Software, San Diego, CA, USA).
Docking studies
An AutoDockVina program (The Scripps Research Institute, CA, USA)was used for docking. 26 The structure of HDAC2 protein in complex with SAHA was obtained from the Protein Data Bank (PDB) (PDB ID: 4LXZ). 27 The coordinates of the compounds were generated by using the GlycoBioChem PRODRG2 Server (http://davapc1.bioch.dun dee.ac.uk/prodrg/). 28 For the docking studies, the grid maps were centered on the SAHA binding site and comprised 26 × 26 × 22 points with 1.0 Å spacing after SAHA was removed from the complex structure, as described in previous works. 17, 18, 20 The AutoDockVina program was performed using eight-way multithreading and the other parameters were default settings.
Prediction of absorption, distribution, metabolism, elimination, and toxicity (ADMET)
In this work ADMET-related properties were computed using Volsurf+ v.1.0.4 and the Chemistry Development Kit (CDK) software (http://cdk.sourceforge.net/). Compound topology was saved as SMILES format (simplified molecular-input line-entry system) using MarvinSketch and further submitted to Volsurf and CDK for molecular descriptor computation. ADMET descriptors comprise Blood-Brain Barrier distribution (logBB), percentage of protein binding (PB, %), volume of distribution (VD, L/kg) and metabolic stability against human CYP3A4 enzyme (MetStab, %). The ability to interact with cytochrome enzyme isoforms (substrate and/or inhibition of CYP3A4, 1A2, 2C9, 2C19, and 2D6) was also checked using admetSAR server developed by Cheng et al. 29 Physicochemical descriptors including molecular weight (MW), partition coefficients (clogP, clogD pH=7.4 ), total polar surface area (PSA, Å 2 ), number of hydrogen bond donors and acceptors, thermodynamic and pH-dependent aqueous solubility (mg/ml) were calculated. In addition, 3PRule was applied to classify permeability across adenocarcinoma (Caco-2) cell membrane 30 -a model commonly used for intestinal absorption estimation. The P-glycoprotein (P-gp, MDR1) substrate states were identified using chemoinformatic approaches developed by Levatic et al. 31 (available at http://pgp.biozyne. com). Lipinski's Rule of Five (Ro5) was also applied to reveal drug-likeness of designed compounds. 32 Finally, in vivo toxicity was predicted by analyzing two risk factors (clogP and PSA) following the same criteria described by Hughes et al. 33 
Results and Discussion
Chemistry
The targeted hydroxamic acids 4-6 were synthesized via three-step pathway, as illustrated in Scheme 1. The first step was a nucleophilic substitution between isatins 1 and propargyl bromide under basic conditions (K 2 CO 3 ) in dimethylformamide (DMF) with a catalytic amount of KI to furnish 1-propargylisatins 2. In the second step, a Click reaction between propargyl compounds 2 and respective methyl azidoalkanoates (including methyl 3-azidopropanoate, methyl 4-azidobutanoate, methyl 5-azidovalerate) gave the intermediate esters 3.
This reaction proceeded smoothly in acetonitrile as a solvent and copper iodide as a catalyst. In most cases, the ester intermediates were precipitated by titration of the reaction residues, which were obtained by evaporation of acetonitrile, with cold water. The final step in the pathway involved a nucleophilic acyl substitution of hydroxylamine hydrochloride with the esters 3. This reaction occurred under alkaline conditions in a solvent mixture which included tetrahydrofuran and methanol at 0-5
• C. The overall yields of compounds 4-6 were moderate.
The structures of the synthesized compounds were determined straightforwardly based on analysis of spectroscopic data, including IR, MS, 1 H and 13 C NMR (Supporting Information). The concurrent condensation of the hydroxylamine with the oxo group at position 3 on the indoline ring under the above conditions occurred in all cases. This condensation has been observed and fully explained previously. 19 
Bioactivity
Due to limited funding resource, in this investigation the compounds synthesized were preliminarily evaluated for histone deacetylase inhibition using HDAC2. We chose HDAC2 because it has been shown that deacetylation of a number of key histone proteins is regulated principally by HDAC2 and HDAC3. HDAC2 has been demonstrated to play very important role in promoting cellular proliferation, while inhibiting normal cell apoptosis. 34 In addition, the compounds were also evaluated for cytotoxicity against three human cancer cell lines, including SW620 (colon cancer), PC3 (prostate cancer), and AsPC-1 (pancreatic cancer). The results are presented in Table 1 .
When designing these compounds, we initially envisioned that the triazole moiety would add more benefits in hydrogen bonding with the amino acid regions in the active binding sites of HDAC, while still serving as a part of a linker between the 2-oxoindoline and hydroxamic acid moieties. Due to shorter length of the C=N and C-N bonds compared to C-C bond, we estimated that if there were only 2C between the triazole and hydroxamic acids, the linker between the 2-oxoindoline and hydroxamic acid moieties (in compounds 4a-c) would be shorter than 6C linker in SAHA. Therefore we decided to design series 5a-g with n = 1 as the target compounds. Series 6a-g with one extra C was also synthesized to compare with series 5a-g. The results presented in Table 1 demonstrate that in series 5a-g and 6a-g, with the exception of a 5-fluorine substituent, other substituents at either position 5 or 7 on the 2-oxoindoline ring generally enhanced HDAC2 inhibition. Also, in overall, series 5a-g inhibited the activity of HDAC2 more potently compared to series 6a-g. A similar trend was also observed with cytotoxicity when comparing series 5a-g and series 6a-g. In series 5a-g, it was found that the relationships between HDAC2 inhibition and cytotoxicity of the compounds were relatively well correlated. Compounds 5d and5e, which were the most potent HDAC2 inhibitors in the series, were also found to be the most cytotoxic against all three cancer cell lines tested. In contrast, compounds 5b and5g, which were the least potent HDAC2 inhibitors in the series, were also among the least cytotoxic ones.
From the results obtained, it is suggested that, when considering the 4-methyl-1H -1,2,3-triazole moiety as a part of a linker between the 3-oxoindoline system and hydroxamic acid group, an alkyl length of three carbon connecting hydroxamic acid and triazole 1H -1,2,3-triazole moieties would be most favorable for bioactivities. Among the compounds synthesized, compound 5f was found to exhibit similar potency in term of HDAC2 inhibition compared to SAHA, meanwhile compound 5e emerged as the most potential candidate with cytotoxicity or up to 8-fold more potent than SAHA in all three cancer cell lines tested. It could be seen that in these two compounds the correlation between HDAC2 inhibitory potency and cytotoxicity was not finely observed. Some reasons might explain for this discrepancy. First, compound 5e could be more potently inhibit other types of HDACs of class I and class II, which are also important in promoting cell proliferation and inhibiting cellular apoptosis. Second, from logP values, it would be possible that compound 5f (with lower logP value of 0.98) was not as good as compound 5e (with higher logP value of 1.44, similar to that of SAHA) in penetrating through cellular membrane.
Docking studies and structure-activity relationships
It has been shown that histone-H3 and histone-H4 deacetylation is regulated principally by HDAC2 and HDAC3. 34 and the crystal structure of HDAC2 in complex with SAHA (PDB ID: 4LXZ) has been reported by Lauffer and co-workers. 27 So we decided to select the structure of SAHA-HDAC2 complex a template in docking experiments to study the structureactivity relationships of these hydroxamic acids and HDAC. Firstly, a control re-docking with co-crystal SAHA to the crystal structures of HDAC2 was executed following the procedures reported previously. 17, 19, 20 The results showed very similar interaction pattern between re-docked and the original SAHA in the crystal structure (the all-atom root-mean-square deviation of 0.609 Å). It was found from docking experiments that all of the hydroxamic acids synthesized were well located in the active site of the enzyme with binding affinities ( G) between −6.7 and −8.1 kcal/mol, comparable or lower than that of SAHA (Table 2 ). It is noted that, in some instances the predicted binding affinities of the compounds were not readily correlated to the experimental data obtained from HDAC2 inhibition assay. For example, the stabilization energies of predicted binding modes on HDAC2 of compounds 5b and 5c were found to be quite similar (−7.7 and −7.8 kcal/mol, respectively). These results were not explainable for the 5-fold difference in the HDAC2 inhibitory effects of compounds 5b and 5c. Especially in case of compound 5f, which has the same calculated stabilization energies as SAHA (−7.4 kcal/mol) was found to exhibit similar potency compared to SAHA in HDAC2 inhibition (IC 50 value was 0.91 µM vs. 1.06 µM of SAHA). Compounds 5e ( G = −8.1 kcal/mol) and5f were two most potent in the series in term of HDAC2 inhibition. Interestingly however, the length of aliphatic chain linking hydroxamic group with triazole ring appeared to be an important factor. There was a remarkable drop in the docking affinity ranges from butanamide to pentanamide moieties, which suggested the negative effect of lengthening the aliphatic chain beyond fourcarbons.
From the docking experiments, it was also found that a zinc ion (grey sphere), which was coordinated by three residues of HDAC2, including Asp181, His183 and Asp269, interacted with all the hydroxamic acid groups in a similar manner as SAHA did. This zinc-chelating functionality has been identified as the dominant factor for inhibitor potency of synthesized hydroxamic derivatives. For all the compounds, it was found that a 1-alkyl-4-methyl-1H -1,2,3-triazole linker between the indoline and hydroxamic acid moieties was tightly stacked between Phe155 and Phe210 residues of the enzymes (Figures 3, 4) and this pi-stacking interaction could be the key factor attributing to the good binding affinities of the compounds with HDAC2.
Interestingly, methyl and methoxy substituents enhanced the interactions between oxoindoline groups and hydrophobic residues at the rim of the pocket, such as Pro34 and Leu276. In these docking experiments, however, the indoline part was found to insignificantly interact with the enzyme. Subsequently, very little variance in the binding affinities among the compounds with different substituted groups was observed. The most potent HDAC2 inhibitor compound 5e and 5f, exhibited extensive hydrogen bonds with His146, Asp181, Glu208 and Tyr308.
ADMET prediction
Today, it is of great interest for modern medicinal chemistry to use computational tools to predict the ADMET properties in parallel with optimizing the bioactive potency of novel chemical entities. 35 Based on the cytotoxicity as well as HDAC2 inhibition potency, we decided to further investigate the ADMET profiles of six derivatives (5a-f and 6c-d) from synthesized compounds using computational approaches.
Firstly, accomplishment of Lipinski's Ro5 was checked in order to roundly predict the drug-likeness of chemicals. 32 All the compounds exceeded the number of five hydrogen bond acceptors, and predicted as possible non-oral drug candidates since recent studies have suggested extending the chemical space beyond Ro5 to avoid lost opportunities, especially for new anticancer agents. 36 As can be appreciated from Table 3 , there is no significant difference of ADME properties calculated. Considering the chemicals as drug-like candidates, we are now discussing some details about the predicted values. Compounds 5e and 5f are very slightly soluble in water (solubility ≥0.01 mg/mL) while others are identified as insoluble ones. 37 Additionally, based on 3PRule developed by Pham-The et al., 30 all the compounds were classified as low intestinal permeability. As stated previously, low permeable compounds are generally absorbed via gastrointestinal tract in a wide range of extent. 37 Interestingly, the poor relationship between permeability classes and lipophilicity (logP) suggests that the transport mechanisms of these analogues are others than passive diffusion. 30 Other ADME parameters of interest were those related to the first-pass metabolism such as P-gp substrate and metabolic stability against cytochrome P450 enzymes. Accordingly, all the compounds were identified to be highly resistant to both P-gp and CYP3A4 metabolism factors. A further inspection of metabolism interactions towards different CYP isoforms revealed that all compounds are both substrate and inhibitor of CYP3A4. They were also predicted to be inhibitors of CYP2C9 while did not interact with other isoforms. On the other hand, the information of plasma protein (mainly albumin) binding (PB) and volume of distribution (VD) is helpful for establishing safety margins and dose regimen of drug candidates. 38 In this aspect, compounds 5e and 5f (with the lowest PB value) could be considered safer than the others. With respect to the drug distribution parameter, all analogues could be moderately distributed in body tissue rather than the plasma since VD > 0.57 l/kg, which is estimated to be total body water volume (> 60% body weight). 39 They also displayed a very low disposition profile in the central nervous system. 40 Lastly, in vivo toxicity of all the compounds was predicted based on two risk factor approaches developed by Hughes and colleagues. 33 The results indicated that the calculated properties are within the drug-like range and any compound concurrently presented both risk factors, such as logP > 3 and PSA < 75 Å 2 . Especially, 5e and 5f have desirable characteristics for anticancer drug candidate.
Conclusions
In conclusion, we have reported a series of 3-hydroxyimino-2-oxoindoline-based hydroxamic acids incorporated with 1-alkyl-4-methyl-1H -1,2,3-triazole linker showing strong HDAC2 inhibitory effects and potent cytotoxicity against several human cancer cell lines, including SW620 (human colon cancer), PC-3 (prostate cancer) and AsPC-1 (pancreas cancer). The results we obtained from this study again confirm that 3-hydroxyimino-2-oxoindolines could well serve as a cap group for hydroxamic acid HDAC inhibitors. Also, different substituents on the benzene ring of the 3-hydroxyimino-2-oxoindoline moiety substantially influence both HDAC inhibition and cytotoxicity of the resulting compounds. Especially, 1-alkyl-4-methyl-1H -1,2,3-triazole linker is tolerable for HDAC inhibitory activity. Computational predictions suggested that compounds 5e and 5f, while showing potent HDAC2 inhibitory bioactivity, hold desirable ADMET characteristics for anticancer compounds. From this study, more extensive bioevaluation and ADMET study are being continued to investigate the potentials of these compounds as anticancer agents.
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